
👨⚕️Oncologista no @hospitalalemao-especializado em câncer de mama,👨👩👦👦pai do Alê, Gui e do Lipe, marido da Monique. ⚽️Corinthians e 🏈Patriots
São Paulo, Brasil
Joined August 2017
- Tweets444
- Following392
- Followers377
- Likes1.5K
Pedro Exman MD, PhD retweeted
Unforgettable lecture by @stolaney1, awarded with the @AACR Outstanding Investigator Award. Her impact on cancer research, leadership, mentorship and pts lives cannot be summarized in a tweet, nor in a thousand. We’re immensely lucky to follow her bright lead at @DFCI_BreastOnc!!
Good time to revisit this post. I would add:
•Maintenance therapy is here to stay.
• PATINA data seem particularly compelling in HR+/HER2+.
•The lack of a statistically CNS benefit with tucatinib is, unfortunately, quite surprising.
#SABCS25 @OncoAlert #bcsm
Precision oncology has reached HER2+ metastatic breast cancer — and additional data on DB09 backs it
🔹 PIK3CA mut → T-DXd, regardless of HR status (🧐?)
🔹 PIK3CA WT →
• HR+ → PATINA-like
• HR− → T-DXd (🤔?)
IHC+NGS may guide up-front choices.
@OncoAlert #bcsm
Pedro Exman MD, PhD retweeted
Please watch @DFCI_BreastOnc #BreastCancerBreakthroughs and learn about new findings in breast oncology. You can learn more at our post-ESMO webinar hosted by @DrHBurstein on Friday, November 14th at 1:30pm EST; register for free here: bit.ly/3WvQUhi
Pedro Exman MD, PhD retweeted
Absolutely AMAZING discussion by Ana Garrido-Castro on ASCENT-03 and TROPiON-Breast02!!!
@DFCI_BreastOnc #ESMO25 @OncoAlert
Precision oncology has reached HER2+ metastatic breast cancer — and additional data on DB09 backs it
🔹 PIK3CA mut → T-DXd, regardless of HR status (🧐?)
🔹 PIK3CA WT →
• HR+ → PATINA-like
• HR− → T-DXd (🤔?)
IHC+NGS may guide up-front choices.
@OncoAlert #bcsm
🙂🙃 Exciting DB05 data — cure rates keep improving!
🔑 For residual post-neoadj disease, treatment escalation with better drugs is needed.
🚨 Fewer patients complete T-Dxd treatment. For lower-risk residual disease, should we do fewer cycles of Txd ?
@OncoAlert @myESMO
Despite the increasing complexity in managing pts after progression on CDK4/6i, these data consolidate that 2nd-line treatment should combine targeted therapy rather than ET monotherapy.
#ESMO25 confirms that next trials should not use isolated fulv as control arm
@OncoAlert
While concerns about the absolute benefit (1.8%) and NNT~50 with adj abema are valid and deserve consideration, the key takeaway may lie in the consistent DRFS gain.
HR 0.75 in distant disease or death is meaningful.
The data is clear — and so is my choice.
@OncoAlert #ESMO25
DFS in the control arm in N0 pts continues to demonstrate meaningful decline — underscoring that these pts may be truly high-risk.
Updated results show a consistent benefit of ribo in this subgroup.
Tumor biology matters to choose wisely the treatment!
@OncoAlert
#ESMO25
Pedro Exman MD, PhD retweeted
monarchE OS w/adj abema--> statistically significant improvement in OS at 7 yrs
OS HR 0.842, p=0.0273; benefit seen across subgroups
iDFS: HR 0.734
DRFS HR 0.746
CDK 4/6i 1L MBC: 47.3% in abema vs 30.0%
If early recurrence 44% on abema arm recv'd chemo in 1L
@myESMO #oncoalert
Pedro Exman MD, PhD retweeted
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
buff.ly/ob4Q2U7
This prospective single-center study evaluated whether the Prosigna 50-gene assay, typically FDA-cleared for postoperative hormone receptor-positive (HR-positive) #BreastCancer could impact neoadjuvant treatment decisions when performed on core biopsy specimens. Among 54 patients with early-stage HR-positive/HER2-negative breast cancer, treatment plans changed in 35.2% of cases after Prosigna results, primarily based on risk of recurrence (ROR) and intrinsic subtype. The assay also bolstered physician confidence in 83.7% of cases and reduced patient anxiety in 62.5%. These findings suggest that using Prosigna in the preoperative setting may meaningfully guide treatment planning and support shared decision-making.
OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @jamecancerdoc @JaniceTNBCmets @itrisabel
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua
Great work, Chiara!
Grateful to kick off this project and, as always, learn alongside @stolaney1 and @nlinmd.
Personalized care is the future — every patient deserves a tailored approach.
Thank you Sara, Nancy and Chiara. @DFCI_BreastOnc
🤓🔬
Pleased to share the results of our prospective observational decision-impact study in early-stage HR+/HER2− breast cancer (NCT03749421).
🔗sciencedirect.com/science/ar…
🧵👇
Pedro Exman MD, PhD retweeted
What an honor to have @lab_kok as the Schlager lecturer at #HarvardBreastCancerCourse. She gave an amazing talk and shared her vision for immunotherapy in early TNBC.
@DFCI_BreastOnc
Pedro Exman MD, PhD retweeted
Three key practice changing trials at #ASCO25, one for each subtype of breast cancer. Things are moving FAST!!!
📢#BreastCancer update from #ASCO25!
Dr @PTarantinoMD shares breast cancer highlights from @ASCO and gives his take on data from
· SERENA-6
· ASCENT-04/KEYNOTE-D19
· DESTINY-Breast09
How will these data impact clinical practice?
📺 Watch the video to find out!
See more updates from ASCO: cor2ed.com/n-connect/program…
#MedEd #OncMedEd #OncTwitter #BCSM
Pedro Exman MD, PhD retweeted
With ASCO25 wrapping up, I wanted to acknowledge the impact of a person that— between leading @DFCI_BreastOnc, caring for patients, mentoring countless physicians, parenting 2 teenagers — also led 2 trials that will impact lives for thousands of pts globally. Congrats @stolaney1!
🚨 Hot take: Among so many studies, OASIS might have the biggest *immediate* impact on pts' lives.
It tackles a side effect that drives poor adherence in breast cancer.
Would love to see discontinuation rates by arm.
We need Elinzanetant available ASAP.
#bcsm @OncoAlert
Pedro Exman MD, PhD retweeted
First-line Sacituzumab + Pembrolizumab improves PFS in 1st Line TNBC. 🚨🔔‼️
Crossover 80% Sacituzumab Offered!
Very few patients with prior IO, few who relapsed within 6-12 months.
OS looks similar but early days.
#bcsm great job @stolaney1 !!
Pedro Exman MD, PhD retweeted
The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at ASCO HERE in Chicago🇺🇸
⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB +PERTUZUMAB (THP) FOR FIRST-LINE (1L) TREATMENT OF HER2+ ADVANCED/METASTATIC BREAST CANCER
⭐LBA4: SERENA-6: CAMIZESTRANT + CDK4/61 IN EMERGENT ESR1 MUTATIONS DURING 1L ET & AHEAD OF DISEASE PROGRESSION IN HR+/HER2- ADV. BREAST CANCER
⭐LBA109: ASCENT-04/KEYNOTE-D19:SACITUZUMAB GOVITECAN + PEMBROLIZUMAB VS CHEMOTHERAPY +PEMBRO IN UNTREATED PD-L1+ ADVANCED TNBC
⭐LBA509:NRG-BRO03:COMPARING DOXORUBICIN PLUS CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL WITH OR W/O CARBOPLATIN FOR NODE+ OR HIGH-RISK NODE-NEGATIVE TNBC
⭐LBA500: NEOCARHP: DE-ESCALATED NEOADJUVANT TAXANE PLUS TRASTUZUMAB AND PERTUZUMAB WITH OR WITHOUT CARBOPLATIN IN HER2-POSITIVE EARLY BREAST CANCER
⭐505: SOFT AND TEXT: ASSESSING BENEFITS FROM ADJUVANT EXEMESTANE + OVARIAN FUNCTION SUPPRESSION OR TAMOXIFEN +OFS.
⭐LBA1005: CCTG/BCT MA.40/FINER: FULVESTRANT AND IPATASERTIB AS TREATMENT FOR ADVANCED HER2- AND ER+ BREAST CANCER FOLLOWING PROGRESSION ON 1L CDK 4/6 INH & AI
⭐LBA1000: VERITAC- 2: VEPDEGESTRANT, A PROTAC ESTROGEN RECEPTOR (ER) DEGRADER, VS FULVESTRANT IN ER+/HER2- ADVANCED BREAST CANCER
⭐1003: INAVO120: 1L INAVOLISIB/PLACEBO + PALBOCICLIB + FULVESTRANT IN PIKCA-MUTATED, HR+, HER2-, ENDOCRINE-RESISTANT ADVANCED BREAST CANCER (ABC).
⭐2005: TUXEDO-3: PATRITUMAB DERUXTECAN (HER3-DXD) IN ACTIVE BRAIN METASTASES (BM) FROM METASTATIC BREAST (MBC) AND NON-SMALL CELL LUNG CANCERS (ANSCLC), AND LEPTOMENINGEAL DISEASE (LMD) FROM ADVANCED SOLID TUMORS
⭐508: OASIS 4: EFFICACY AND SAFETY OF ELINZANETANT FOR VASOMOTOR SYMPTOMS ASSOCIATED WITH ADJUVANT ENDOCRINE THERAPY
LEADS: @ElisaAgostinett @to_be_elizabeth @WeOncologists
Senior Faculty: @matteolambe @E_de_Azambuja @ErikaHamilton9 Fatima Cardoso @ABCGlobalAll @maryam_lustberg @hoperugo
Co Leads: @GaiaGriguolo @JankovicK
Breast cancer Faculty
@aftimosp @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @double_whammied @stage4kelly @coffeemommy @itsnot_pink @IBCResearch @kevinpunie @nicolobattisti @raalbany @stolaney1 @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@bavilima @realbowtiedoc @Erman_Akkus @Lucarecco
Thinking about this algorithm…
Two critical questions: assess and access
🧬 When should we ASSESS tumor mutations? At diagnosis ? 1st recurrence? And then rely on liquid biopsy for 2nd line?
🤔 How can we improve ACCESS to this approach for more patients?
@OncoAlert #bcsm
Very intriguing trial at the start of #ASCO25
ABC study. It tackles an unmet need with a rational, synergistic combo — ICI + platinum + anti-angiogenic therapy.
Small study (n=35), but CNS-ORR 77% — including CR 14% 😳 — is striking.
Definitely one to watch
#bcsm @OncoAlert































